Pestalozzi advised Promethera Biosciences SA in connection with its acquisition of Baliopharm AG
On 10 April 2018, Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases based in Mont-Saint-Guibert, Belgium, announced that it has acquired Baliopharm AG, a Swiss biopharmaceutical company focused on the development of targeted biological therapies for immune mediated inflammatory diseseas and cancer. Pestalozzi advised Promethera on Swiss law aspects of this transaction.
The Pestalozzi team included:
Zurück zur Übersicht